AstraZeneca(US:AZN) Zhi Tong Cai Jing·2025-11-06 13:55Core Insights - AstraZeneca (AZN.US) shares rose over 4% pre-market, reaching $84.92 following the release of its Q3 earnings report [1] - The company reported a 12% year-over-year increase in total revenue to $15.191 billion, with core earnings per share (EPS) of $2.38, exceeding market expectations of $2.27, driven by strong sales of key cancer and diabetes drugs [1] - For the first nine months, revenue grew by 10% year-over-year to $43.236 billion, with core EPS at $7.04 [1] - AstraZeneca reaffirmed its guidance for the full year, expecting high single-digit revenue growth and low double-digit core EPS growth, aligning with market expectations [1] - The company plans to announce a full-year dividend of $3.20 per share for 2025, up from $3.10 last year [1]